Osanni Bio raises $190 million Series B to advance therapeutics platform

Funding Rounds

▤ Summary

Osanni Bio secured $190 million in Series B financing led by Patient Square Capital. Existing investors Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund also joined the round. The company plans to use the capital to advance its pipeline and expand its discovery and development process. This news signals continued investment in life sciences innovation and operating scale.

$ Funding

$
Amount $190.0M Total raised
□
Date June 24, 2026 Announcement date
◎
Investors Retinal Degeneration Fund, Horowitz Group, Patient Square Capital Lead investors
▥
Company osanni.bio Funded company

▥ Classifications

industries
HealthTech
applications
ERP & Process Management

◇ AskAI Classifications

Labels
SaaS Recruitment Software Sales Enablement Software

▦ Linked Companies